1416 related articles for article (PubMed ID: 12658727)
21. Novel expression of gastrin (cholecystokinin-B) receptors in azaserine-induced rat pancreatic carcinoma: receptor determination and characterization.
Zhou W; Povoski SP; Longnecker DS; Bell RH
Cancer Res; 1992 Dec; 52(24):6905-11. PubMed ID: 1458479
[TBL] [Abstract][Full Text] [Related]
22. Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting.
Reubi C; Gugger M; Waser B
Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):855-62. PubMed ID: 12111125
[TBL] [Abstract][Full Text] [Related]
23. Characterization of cholecystokinin receptors and messenger RNA expression in rat pancreas: evidence for expression of cholecystokinin-A receptors but not cholecystokinin-B (gastrin) receptors.
Zhou W; Povoski SP; Bell RH
J Surg Res; 1995 Mar; 58(3):281-9. PubMed ID: 7533864
[TBL] [Abstract][Full Text] [Related]
24. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
Hofland LJ; Lamberts SW; van Hagen PM; Reubi JC; Schaeffer J; Waaijers M; van Koetsveld PM; Srinivasan A; Krenning EP; Breeman WA
J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423
[TBL] [Abstract][Full Text] [Related]
25. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
26. Phylogeny of the cholecystokinin/gastrin family.
Johnsen AH
Front Neuroendocrinol; 1998 Apr; 19(2):73-99. PubMed ID: 9578981
[TBL] [Abstract][Full Text] [Related]
27. The cholecystokinin2-receptor mediates calcitonin secretion, gene expression, and proliferation in the human medullary thyroid carcinoma cell line, TT.
Bläker M; Arrenberg P; Stange I; Schulz M; Burghardt S; Michaelis H; Pace A; Greten H; von Schrenck T; de Weerth A
Regul Pept; 2004 Apr; 118(1-2):111-7. PubMed ID: 14759564
[TBL] [Abstract][Full Text] [Related]
28. Radiochemical investigations of [188Re(H2O)(CO)3-diaminopropionic acid-SSS-bombesin(7-14)NH2]: syntheses, radiolabeling and in vitro/in vivo GRP receptor targeting studies.
Smith CJ; Sieckman GL; Owen NK; Hayes DL; Mazuru DG; Volkert WA; Hoffman TJ
Anticancer Res; 2003; 23(1A):63-70. PubMed ID: 12680195
[TBL] [Abstract][Full Text] [Related]
29. Identification of cholecystokinin-B/gastrin receptor domains that confer high gastrin affinity: utilization of a novel Xenopus laevis cholecystokinin receptor.
Schmitz F; Pratt DS; Wu MJ; Kolakowski LF; Beinborn M; Kopin AS
Mol Pharmacol; 1996 Aug; 50(2):436-41. PubMed ID: 8700154
[TBL] [Abstract][Full Text] [Related]
30. Peptide/benzodiazepine hybrids as ligands of CCK(A) and CCK(B) receptors.
Escherich A; Lutz J; Escrieut C; Fourmy D; van Neuren AS; Müller G; Schafferhans A; Klebe G; Moroder L
Biopolymers; 2000-2001; 56(2):55-76. PubMed ID: 11592053
[TBL] [Abstract][Full Text] [Related]
31. Antiserum raised against an epitope of the cholecystokinin B/gastrin receptor inhibits hepatic invasion of a human colon tumor.
Watson SA; Clarke PA; Morris TM; Caplin ME
Cancer Res; 2000 Oct; 60(20):5902-7. PubMed ID: 11059789
[TBL] [Abstract][Full Text] [Related]
32. Radiolabeled gastrin/CCK analogs in tumor diagnosis: towards higher stability and improved tumor targeting.
Kaloudi A; Nock BA; Krenning EP; Maina T; De Jong M
Q J Nucl Med Mol Imaging; 2015 Sep; 59(3):287-302. PubMed ID: 26158215
[TBL] [Abstract][Full Text] [Related]
33. Stabilized (111)in-labeled sCCK8 analogues for targeting CCK2-receptor positive tumors: synthesis and evaluation.
Roosenburg S; Laverman P; Joosten L; Eek A; Oyen WJ; de Jong M; Rutjes FP; van Delft FL; Boerman OC
Bioconjug Chem; 2010 Apr; 21(4):663-70. PubMed ID: 20302291
[TBL] [Abstract][Full Text] [Related]
34. Expression of the cholecystokinin 2-receptor in normal human thyroid gland and medullary thyroid carcinoma.
Blaker M; de Weerth A; Tometten M; Schulz M; Höppner W; Arlt D; Hoang-Vu C; Dralle H; Terpe H; Jonas L; von Schrenck T
Eur J Endocrinol; 2002 Jan; 146(1):89-96. PubMed ID: 11751073
[TBL] [Abstract][Full Text] [Related]
35. Cyclic minigastrin analogues for gastrin receptor scintigraphy with technetium-99m: preclinical evaluation.
von Guggenberg E; Sallegger W; Helbok A; Ocak M; King R; Mather SJ; Decristoforo C
J Med Chem; 2009 Aug; 52(15):4786-93. PubMed ID: 19591486
[TBL] [Abstract][Full Text] [Related]
36. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.
De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP
Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786
[TBL] [Abstract][Full Text] [Related]
37. Mapping of ligand binding sites of the cholecystokinin-B/gastrin receptor with lipo-gastrin peptides and molecular modeling.
Lutz J; Romano-Götsch R; Escrieut C; Fourmy D; Mathä B; Müller G; Kessler H; Moroder L
Biopolymers; 1997 Jun; 41(7):799-817. PubMed ID: 9128441
[TBL] [Abstract][Full Text] [Related]
38. Further evidence for a C-terminal structural motif in CCK2 receptor active peptide hormones.
Stone SR; Giragossian C; Mierke DF; Jackson GE
Peptides; 2007 Nov; 28(11):2211-22. PubMed ID: 17950490
[TBL] [Abstract][Full Text] [Related]
39. Biodistribution and elimination characteristics of two 111In-labeled CCK-2/gastrin receptor-specific peptides in rats.
Trejtnar F; Laznicek M; Laznickova A; Kopecky M; Petrik M; Béhé M; Schmidt J; Maecke H; Maina T; Nock B
Anticancer Res; 2007; 27(2):907-12. PubMed ID: 17465219
[TBL] [Abstract][Full Text] [Related]
40. Expression of cholecystokinin-B/gastrin receptors in medullary thyroid cancer.
Amiri-Mosavi A; Ahlman H; Tisell LE; Wängberg B; Kölby L; Forssell-Aronsson E; Lundberg PA; Lindstedt G; Nilsson O
Eur J Surg; 1999 Jul; 165(7):628-31. PubMed ID: 10452255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
